Product Would Be The Second Complete, Fixed-Dose Antiretroviral Regimen FOSTER TOWN, Calif.–(Healthcare Sales & Marketing Network)–Gilead Sciences, Inc. (Nasdaq:GILD ) today announced that it has submitted a Marketing Authorization Application (MAA) t…
Biopharmaceuticals, HIV/AIDS
Gilead Sciences, Tibotec Pharmaceuticals, Truvada

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Gilead Sciences Submits European Marketing Application for Once-Daily Single-Tablet Regimen of Truvada(R) and TMC278 for the Treatment of HIV Infection”
Leave a Comment